2 Information about sodium zirconium cyclosilicate

2 Information about sodium zirconium cyclosilicate

Marketing authorisation indication

Sodium zirconium cyclosilicate (Lokelma, AstraZeneca) has a marketing authorisation 'for the treatment of hyperkalaemia in adult patients'.

Dosage in the marketing authorisation

Correction phase:

The recommended starting dose of sodium zirconium cyclosilicate is 10 g, administered 3 times a day orally as a suspension in water. When normal serum potassium levels are reached, the maintenance regimen should be followed. If normal serum potassium levels are not reached after 72 hours of treatment, sodium zirconium cyclosilicate should be stopped.

Maintenance phase:

For people with normal serum potassium levels after the correction phase, the minimal effective dose of sodium zirconium cyclosilicate to prevent recurrence of hyperkalaemia should be established. A starting dose of 5 g once daily is recommended, with possible titration up to a maximum of 10 g once daily or down to 5 g once every other day as needed to maintain a normal serum potassium level.

Price

The list price of sodium zirconium cyclosilicate is £14.24 per 10-g sachet or £7.12 per 5-g sachet (Specialist Pharmacy Service, accessed June 2019).

The company has a commercial arrangement. This makes sodium zirconium cyclosilicate available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)